European-Australasian consensus on the management of advanced gastric and gastro-oesophageal junction cancer: current practice and new directions.
antiangiogenesis
chemotherapy
gastric adenocarcinoma
gastro-oesophageal junction
immune checkpoint inhibitors
refractory disease
Journal
Therapeutic advances in medical oncology
ISSN: 1758-8340
Titre abrégé: Ther Adv Med Oncol
Pays: England
ID NLM: 101510808
Informations de publication
Date de publication:
2022
2022
Historique:
received:
05
04
2022
accepted:
25
07
2022
entrez:
2
9
2022
pubmed:
3
9
2022
medline:
3
9
2022
Statut:
epublish
Résumé
Gastric carcinoma and gastro-oesophageal junction (GC/GEJ) carcinoma remain a significant global problem, with patients presenting with symptoms often found to have advanced or metastatic disease. Treatment options for these patients have broadened in recent years with new chemotherapy agents, agents targeting angiogenic pathways and the development of immune checkpoint inhibitors (ICIs). Most initial advances have occurred in the refractory setting, where it is important to balance treatment benefits
Identifiants
pubmed: 36051471
doi: 10.1177/17588359221118874
pii: 10.1177_17588359221118874
pmc: PMC9425884
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
17588359221118874Informations de copyright
© The Author(s), 2022.
Déclaration de conflit d'intérêts
Competing Interests: All authors have no COI directly related to this work. BUT COI Statements from authors with industry unrelated to this work are as follows: Nick Pavlakis: Advisory Boards MSD, Merck, BMS, Takeda, Beigene, Astra Zeneca, Roche, Amgen, Novartis Speaking Honoraria Roche, Pierre-Faber Research Funding – to institution Bayer, Roche Christos Karapetis: Advisory Board Amgen, Astra Zeneca, Beigene, BMS, Eli Lilly, Eisai, Ipsen, Merck, MSD, Pierre Fabre, Roche, Takeda Timothy Price: Advisory Board MSD, Merck Serono, Pierre Fabre, BMS, Servier Radka Obermannova: Personal fee BMS, Merck, MSD, Servie Research support (to institution): Roche Florian Lordick: Honorari BMS, MSD, Roche, Astra Zeneca Lorraine Chantrill: Advisory Board Pierre Fabre, AstraZeneca, BMS, Merck
Références
Lancet. 2010 Aug 28;376(9742):687-97
pubmed: 20728210
N Engl J Med. 2020 Dec 3;383(23):2207-2218
pubmed: 33264544
Cancer Discov. 2018 Jan;8(1):37-48
pubmed: 28978556
Lancet. 2021 Aug 28;398(10302):759-771
pubmed: 34454674
Nat Rev Clin Oncol. 2021 Aug;18(8):473-487
pubmed: 33790428
Ann Oncol. 2018 Oct 1;29(10):2052-2060
pubmed: 30052729
Gastric Cancer. 2015 Jul;18(3):476-84
pubmed: 25038874
N Engl J Med. 2015 Feb 19;372(8):724-34
pubmed: 25693012
Gut. 2019 Jul;68(7):1152-1161
pubmed: 30269082
Ann Oncol. 2019 Jan 1;30(1):19-33
pubmed: 30475956
Lancet Oncol. 2022 Feb;23(2):234-247
pubmed: 35030335
Oncotarget. 2017 Jan 26;8(34):57654-57669
pubmed: 28915702
Lancet Gastroenterol Hepatol. 2020 Jan;5(1):42-54
pubmed: 31648970
JAMA Oncol. 2020 Oct 1;6(10):1571-1580
pubmed: 32880601
Ann Oncol. 2016 Sep;27(suppl 5):v38-v49
pubmed: 27664260
Eur J Cancer. 2011 Oct;47(15):2306-14
pubmed: 21742485
J Clin Oncol. 2016 May 1;34(13):1448-54
pubmed: 26884585
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Lancet Oncol. 2019 Mar;20(3):420-435
pubmed: 30718072
Gastric Cancer. 2020 Jul;23(4):689-698
pubmed: 32128634
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255
Nature. 2021 Dec;600(7890):727-730
pubmed: 34912120
Exp Mol Med. 2020 Sep;52(9):1475-1485
pubmed: 32913278
Lancet. 2014 Jan 4;383(9911):31-39
pubmed: 24094768
Lancet Oncol. 2018 Nov;19(11):1437-1448
pubmed: 30355453
J Immunother Cancer. 2019 Oct 26;7(1):278
pubmed: 31655605
Ann Surg Oncol. 2008 Jun;15(6):1644-50
pubmed: 18392661
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Lancet Oncol. 2018 Oct;19(10):1372-1384
pubmed: 30217672
Nature. 2014 Sep 11;513(7517):202-9
pubmed: 25079317
Oncotarget. 2016 Aug 9;7(32):52307-52316
pubmed: 27447571
Cochrane Database Syst Rev. 2017 Aug 29;8:CD004064
pubmed: 28850174
J Clin Oncol. 2012 May 1;30(13):1513-8
pubmed: 22412140
Nat Med. 2018 May;24(5):541-550
pubmed: 29686425
Br J Cancer. 2016 Feb 16;114(4):381-7
pubmed: 26882063
J Clin Oncol. 2016 Aug 10;34(23):2728-35
pubmed: 27325864
ESMO Open. 2021 Aug;6(4):100200
pubmed: 34175675
Lancet Oncol. 2014 Jan;15(1):78-86
pubmed: 24332238
N Engl J Med. 2017 Jul 13;377(2):122-131
pubmed: 28581356
Cancer Discov. 2019 Oct;9(10):1388-1405
pubmed: 31315834
Ann Oncol. 2009 Apr;20(4):666-73
pubmed: 19153121
N Engl J Med. 2012 Jan 12;366(2):109-19
pubmed: 22149875
Lancet Oncol. 2014 Oct;15(11):1224-35
pubmed: 25240821
JAMA Oncol. 2021 Jun 01;7(6):895-902
pubmed: 33792646
Cancer Discov. 2018 Jan;8(1):49-58
pubmed: 29122777
Ther Adv Med Oncol. 2022 Mar 8;14:17588359221083049
pubmed: 35281349
Lancet. 2020 Aug 29;396(10251):635-648
pubmed: 32861308
J Clin Oncol. 2020 Jun 20;38(18):2053-2061
pubmed: 32343640
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
J Clin Oncol. 2008 Mar 20;26(9):1435-42
pubmed: 18349393
JAMA Oncol. 2018 May 10;4(5):e180013
pubmed: 29543932
Ann Oncol. 2008 Sep;19(9):1523-9
pubmed: 18441328
Lancet. 2018 Jul 14;392(10142):123-133
pubmed: 29880231
J Clin Oncol. 2011 Oct 20;29(30):3968-76
pubmed: 21844504
J Clin Oncol. 2021 Mar 20;39(9):966-977
pubmed: 33197226
N Engl J Med. 2012 Jun 28;366(26):2517-9
pubmed: 22658126
J Clin Oncol. 2014 Nov 1;32(31):3520-6
pubmed: 25287828
N Engl J Med. 2020 Jun 18;382(25):2419-2430
pubmed: 32469182
Cancer Treat Rev. 2022 Jul;108:102418
pubmed: 35689885
Lancet. 2021 Jul 3;398(10294):27-40
pubmed: 34102137
Ann Oncol. 2009 Sep;20(9):1529-1534
pubmed: 19474114
Lancet. 2017 Dec 2;390(10111):2461-2471
pubmed: 28993052